BFS
BBIO icon

Bare Financial Services’s BridgeBio Pharma BBIO Stock Holding History

Bare Financial Services’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$817 Sell
11
-7
-39% -$507 ﹤0.01% 1338
2025
Q4 		$1.38K Buy
18
+7
+64% +$459 ﹤0.01% 1004
2025
Q3 		$571 Buy
+11
New +$536 ﹤0.01% 1213

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bare Financial Services's BBIO Position: Q1 2026 in Review

Bare Financial Services reduced its BridgeBio Pharma (BBIO) stake by 39% in Q1 2026, selling an estimated $507 and leaving 11 shares worth $817. The position accounts for ﹤0.01% of the portfolio, ranked #1338.

Bare Financial Services first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.38K in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Bare Financial Services held 11 shares of BridgeBio Pharma worth $817 as of Q1 2026.
  • Bare Financial Services sold 7 BridgeBio Pharma shares in Q1 2026, an estimated $507.
  • BridgeBio Pharma made up ﹤0.01% of Bare Financial Services's portfolio in Q1 2026, its #1338 holding.
  • Bare Financial Services first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
  • Bare Financial Services's BridgeBio Pharma position peaked at $1.38K in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Bare Financial Services's 13F filing for Q1 2026, filed 14 May 2026.